Skip to main content
Johnson & JohnsonIn development

Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.

What happened

Johnson & Johnson is developing an investigational dual-antigen immunotherapy combination of pasritamig and JNJ-9401 for the treatment of advanced prostate cancer, with the regimen entering Phase 3 development.

Source

Article excerpt

NEW BRUNSWICK, N.J., Nov. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced promising first-in-human Phase 1 results for the investigational combination of pasritamig and JNJ-9401, two bispecific antibodies designed to work together to drive the body's immune response against advanced prostate cancer. At the recommended regimen, 73 percent (11 of 15 patients) achieved reductions of at least 50 percent in prostate-specific antigen (PSA), a marker used to monitor prostate cancer activity, including 47 percent (7 of 15 patients) who achieved reductions of at least 90 percent. Results were presented in a late-breaking oral session at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting (Abstract #1175). 1 The combination represents the first dual-tumor-antigen-targeted bispecific antibody regimen clinically evaluated in prostate cancer, targeting kallikrein-related peptidase 2 (KLK2) and prostate-specific membrane antigen (PSMA) through complementary T-cell signals designed to activate and enhance the function of immune cells against cancer. In the study, deep and sustained PSA responses were observed, with all seven patients who achieved reductions of at least 90 percent remaining on treatment for more than six months without disease progression. No Grade 3 or higher treatment-related adverse events were reported in this early analysis. 1 A...

Keep reading with a free account

The rest of this article, and every signal for Johnson & Johnson, is in your free account.

Extracted from this sentence

With this combination now in Phase 3 development, we are building on the early promise of this approach as we work to bring new treatment options to patients with advanced disease.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
pasritamig and JNJ-9401 combination
Location
New Brunswick, New Jersey, United States

The full record

From the Signal API record

Details

Ticker
NYSE:JNJ

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Nov 8, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Johnson & Johnson and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/dd2d76ea-cf47-0ac0-162f-c4b6c6a0dabb returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.

{
  "signal_id": "dd2d76ea-cf47-0ac0-162f-c4b6c6a0dabb",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-08T16:00:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/johnson--johnson-reports-73-psa-response-rate-with-investigational-pasritamig-based-immunotherapy-combination-in-advanced-prostate-cancer-302932750.html",
    "title": "Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer",
    "ticker": "NYSE:JNJ",
    "excerpt": "NEW BRUNSWICK, N.J. , Nov. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced promising first-in-human Phase 1 results for the investigational combination of pasritamig and JNJ-9401, two bispecific antibodies designed to work together to drive the body's immune response against advanced prostate cancer. At the recommended regimen, 73 percent (11 of 15 patients) achieved reductions of at least 50 percent in prostate-specific antigen (PSA), a marker used to monitor prostate cancer activity, including 47 percent (7 of 15 patients) who achieved reductions of at least 90 percent. Results were presented in a late-breaking oral session at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting (Abstract #1175). 1 The combination represents the first dual-tumor-antigen-targeted bispecific antibody regimen clinically evaluated in prostate cancer, targeting kallikrein-related peptidase 2 (KLK2) and prostate-specific membrane antigen (PSMA) through complementary T-cell signals designed to activate and enhance the function of immune cells against cancer. In the study, deep and sustained PSA responses were observed, with all seven patients who achieved reductions of at least 90 percent remaining on treatment for more than six months without disease progression. No Grade 3 or higher treatment-related adverse events were reported in this early analysis. 1 A...",
    "product": "pasritamig and JNJ-9401 combination",
    "summary": "Johnson & Johnson is developing an investigational dual-antigen immunotherapy combination of pasritamig and JNJ-9401 for the treatment of advanced prostate cancer, with the regimen entering Phase 3 development.",
    "location": "New Brunswick, New Jersey, United States",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS225644/Johnson-and-Johnson-Logo-v1.jpg?id=OA3064454&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "pasritamig and JNJ-9401 combination",
      "full_text": "investigational combination of pasritamig and JNJ-9401",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-11-08T16:00:00Z",
    "location_data": [
      {
        "city": "New Brunswick",
        "state": "New Jersey",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "With this combination now in Phase 3 development, we are building on the early promise of this approach as we work to bring new treatment options to patients with advanced disease."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.